CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-05 | GRYSKA DAVID W Director | Purchase | +2,500 | $7.17 | $18K | 19,851 |
| 2024-09-25 | Liao Carrie Chief Accounting Officer | Sale 10b5-1 | −2,352 | $5.98 | $14K | 99,543 |
| 2024-09-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −19,771 | $5.98 | $118K | 545,772 |
| 2024-09-25 | Karlin Dan Chief Medical Officer | Sale 10b5-1 | −6,871 | $5.98 | $41K | 344,656 |
| 2024-09-25 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −4,430 | $5.98 | $26K | 177,716 |
| 2024-08-23 | GRYSKA DAVID W Director | Purchase | +3,500 | $5.98 | $21K | 17,351 |
| 2024-08-21 | Halperin Wernli Miri Executive President | Option exercise | +50,000 | $3.70 | $185K | 235,000 |
| 2024-08-21 | Halperin Wernli Miri Executive President | Shares withheld for taxes | −32,595 | $6.17 | $201K | 202,405 |
| 2024-08-21 | Halperin Wernli Miri Executive President | Option exercise · Stock Option (Right to Buy) | −50,000 | 0 | ||
| 2024-08-20 | Barrow Robert Chief Executive Officer | Purchase | +500 | $6.12 | $3K | 565,543 |
| 2024-08-19 | Barrow Robert Chief Executive Officer | Purchase | +500 | $6.31 | $3K | 565,043 |
| 2024-06-25 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −17,854 | $7.22 | $129K | 182,146 |
| 2024-06-25 | Karlin Dan Chief Medical Officer | Sale 10b5-1 | −6,925 | $7.22 | $50K | 351,527 |
| 2024-06-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −15,659 | $7.22 | $113K | 564,543 |
| 2024-06-10 | Vallone Carol A Director | Grant or award · Stock Option (Right to Buy) | +16,506 | 16,506 | ||
| 2024-06-10 | GRYSKA DAVID W Director | Grant or award · Stock Option (Right to Buy) | +16,506 | 16,506 | ||
| 2024-06-10 | CRYSTAL ROGER Director | Grant or award · Stock Option (Right to Buy) | +16,506 | 16,506 | ||
| 2024-06-10 | Bruhn Suzanne Louise Director | Grant or award · Stock Option (Right to Buy) | +16,506 | 16,506 | ||
| 2024-06-10 | Krebs Andreas Director | Grant or award · Stock Option (Right to Buy) | +16,506 | 16,506 | ||
| 2024-03-25 | Greenway Schond L. Chief Financial Officer | Shares withheld for taxes | −5,560 | $9.78 | $54K | 211,057 |
Page 5 of 12 · 225 trades